Ashish A Deshmukh1, Jagpreet Chhatwal2, Elizabeth Y Chiao3, Alan G Nyitray4, Prajnan Das5, Scott B Cantor6. 1. Department of Health Services Research Cancer Prevention Training Research Program. 2. Institute for Technology Assessment, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts. 3. Department of Medicine, Section of Infectious Disease, Baylor College of Medicine, Houston, Texas. 4. Division of Epidemiology, Human Genetics, and Environmental Sciences, The University of Texas Health Science Center School of Public Health. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center. 6. Department of Health Services Research.
Abstract
BACKGROUND: Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in men who have sex with men (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a 50% reduction in the risk of recurrent HGAIN. We evaluated the long-term clinical and economic outcomes of adding the qHPV vaccine to the treatment regimen for HGAIN in human immunodeficiency virus (HIV)-positive MSM aged ≥27 years. METHODS: We constructed a Markov model based on anal histology in HIV-positive MSM comparing qHPV vaccination with no vaccination after treatment for HGAIN, the current practice. The model parameters, including baseline prevalence, disease transitions, costs, and utilities, were either obtained from the literature or calibrated using a natural history model of anal carcinogenesis. The model outputs included lifetime costs, quality-adjusted life years, and lifetime risk of developing anal cancer. We estimated the incremental cost-effectiveness ratio of qHPV vaccination compared to no qHPV vaccination and decrease in lifetime risk of anal cancer. We also conducted deterministic and probabilistic sensitivity analyses to evaluate the robustness of the results. RESULTS: Use of qHPV vaccination after treatment for HGAIN decreased the lifetime risk of anal cancer by 63% compared with no vaccination. The qHPV vaccination strategy was cost saving; it decreased lifetime costs by $419 and increased quality-adjusted life years by 0.16. Results were robust to the sensitivity analysis. CONCLUSIONS: Vaccinating HIV-positive MSM aged ≥27 years with qHPV vaccine after treatment for HGAIN is a cost-saving strategy. Therefore, expansion of current vaccination guidelines to include this population should be a high priority.
BACKGROUND: Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in men who have sex with men (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a 50% reduction in the risk of recurrent HGAIN. We evaluated the long-term clinical and economic outcomes of adding the qHPV vaccine to the treatment regimen for HGAIN in human immunodeficiency virus (HIV)-positive MSM aged ≥27 years. METHODS: We constructed a Markov model based on anal histology in HIV-positive MSM comparing qHPV vaccination with no vaccination after treatment for HGAIN, the current practice. The model parameters, including baseline prevalence, disease transitions, costs, and utilities, were either obtained from the literature or calibrated using a natural history model of anal carcinogenesis. The model outputs included lifetime costs, quality-adjusted life years, and lifetime risk of developing anal cancer. We estimated the incremental cost-effectiveness ratio of qHPV vaccination compared to no qHPV vaccination and decrease in lifetime risk of anal cancer. We also conducted deterministic and probabilistic sensitivity analyses to evaluate the robustness of the results. RESULTS: Use of qHPV vaccination after treatment for HGAIN decreased the lifetime risk of anal cancer by 63% compared with no vaccination. The qHPV vaccination strategy was cost saving; it decreased lifetime costs by $419 and increased quality-adjusted life years by 0.16. Results were robust to the sensitivity analysis. CONCLUSIONS: Vaccinating HIV-positive MSM aged ≥27 years with qHPV vaccine after treatment for HGAIN is a cost-saving strategy. Therefore, expansion of current vaccination guidelines to include this population should be a high priority.
Authors: Eric C Seaberg; Dorothy Wiley; Otoniel Martínez-Maza; Joan S Chmiel; Lawrence Kingsley; Yiwei Tang; Joseph B Margolick; Lisa P Jacobson Journal: Cancer Date: 2010-07-29 Impact factor: 6.860
Authors: Andrew N Phillips; Brian Gazzard; Richard Gilson; Philippa Easterbrook; Margaret Johnson; John Walsh; Clifford Leen; Martin Fisher; Chloe Orkin; Jane Anderson; Deenan Pillay; Valerie Delpech; Caroline Sabin; Achim Schwenk; David Dunn; Mark Gompels; Teresa Hill; Kholoud Porter; Abdel Babiker Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri Journal: MMWR Morb Mortal Wkly Rep Date: 2014-07-25 Impact factor: 17.586
Authors: Ashish A Deshmukh; Elizabeth Y Chiao; Scott B Cantor; Elizabeth A Stier; Stephen E Goldstone; Alan G Nyitray; Timothy Wilkin; Xiaojie Wang; Jagpreet Chhatwal Journal: Cancer Date: 2017-09-26 Impact factor: 6.860
Authors: Ashish A Deshmukh; Scott B Cantor; Elisabeth Fenwick; Elizabeth Y Chiao; Alan G Nyitray; Elizabeth A Stier; Stephen E Goldstone; Timothy Wilkin; Jagpreet Chhatwal Journal: Vaccine Date: 2017-08-12 Impact factor: 3.641
Authors: C Sadlier; A Lynam; S O'Dea; S Delamere; M Quinlan; S Clarke; O Sheils; C Bergin Journal: Hum Vaccin Immunother Date: 2016-05-06 Impact factor: 3.452